ArticleDiabetic medicine : a journal of the British Diabetic Association2021
Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Prevalence and impact of polypharmacy in older patients with type 2 diabetes.Aging clinical and experimental research · 2022Pooled it
- Wise Prescriptions: Prevalence and Predictors of Polypharmacy in Patients with Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Management strategies in older adults with diabetes mellitus and polypharmacy; a narrative review.Hormones (Athens, Greece) · 2026Review
- The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes.Clinical pharmacology and therapeutics · 2026Article
- The Interaction of Health Behaviors and Cardiovascular Diseases: Investigating Morbidity Risks of Disparities in U.S. Adults.Healthcare (Basel, Switzerland) · 2025Article
- Polypharmacy in older patients with diabetes mellitus: a population based-study of northern Italy.Acta diabetologica · 2025Article
- Examining the relationship between adherence and the number of cardiometabolic medications: Findings for patients with type 2 diabetes within a Tribal health care system.Journal of managed care & specialty pharmacy · 2025Article
- Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.Advances in therapy · 2023Article
- Prevalence and trends of polypharmacy in U.S. adults, 1999-2018.Global health research and policy · 2023Article
- Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes.Endocrine reviews · 2023Article
- Hypertension in diabetes care: emerging roles of recent hypoglycemic agents.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the prevalence and characteristics of polypharmacy in a Dutch cohort of individuals with type 2 diabetes.
methodsWe included people with type 2 diabetes from the Diabetes Pearl cohort, of whom 3886 were treated in primary care and 2873 in academic care (secondary/tertiary). With multivariable multinomial logistic regression analyses stratified for line of care, we assessed which sociodemographic, lifestyle and cardiometabolic characteristics were associated with moderate (5-9 medications) and severe polypharmacy (≥10 medications) compared with no polypharmacy (0-4 medications).
resultsMean age was 63 ± 10 years, and 40% were women. The median number of daily medications was 5 (IQR 3-7) in primary care and 7 (IQR 5-10) in academic care. The prevalence of moderate and severe polypharmacy was 44% and 10% in primary care, and 53% and 29% in academic care respectively. Glucose-lowering and lipid-modifying medications were most prevalent. People with severe polypharmacy used a relatively large amount of other (i.e. non-cardiovascular and non-glucose-lowering) medication. Moderate and severe polypharmacy across all lines of care were associated with higher age, low educational level, more smoking, longer diabetes duration, higher BMI and more cardiovascular disease.
conclusionsSevere and moderate polypharmacy are prevalent in over half of people with type 2 diabetes in primary care, and even more in academic care. People with polypharmacy are characterized by poorer cardiometabolic status. These results highlight the significance of polypharmacy in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.